Feb 7, 2019   SOURCE: PR NewsWire

Global Targeted Drug Delivery Partnering Deals and Agreements 2012-2018

DUBLIN, Feb. 7, 2019 /PRNewswire/ --

The "Global Targeted Drug Delivery Partnering 2012-2018: Deal trends, players, financials and forecasts" report has been added to ResearchAndMarkets.com's offering.

https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

Targeted Drug Delivery Partnering 2012-2018 report provides understanding and access to the targeted drug delivery partnering deals and agreements entered into by the world's leading healthcare companies. This report provides details of the latest Targeted Drug Delivery agreements announced in the life sciences since 2012.

The report takes the reader through a comprehensive review Targeted Drug Delivery deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Targeted Drug Delivery partnering deals.

The report presents financial deal term values for Targeted Drug Delivery deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Targeted Drug Delivery partnering field; both the leading deal values and most active Targeted Drug Delivery dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 160 online deal records of actual Targeted Drug Delivery deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

Analyzing actual contract agreements allows assessment of the following:

    --  What are the precise rights granted or optioned?
    --  What is actually granted by the agreement to the partner company?
    --  What exclusivity is granted?
    --  What is the payment structure for the deal?
    --  How are sales and payments audited?
    --  What is the deal term?
    --  How are the key terms of the agreement defined?
    --  How are IPRs handled and owned?
    --  Who is responsible for commercialization?
    --  Who is responsible for development, supply, and manufacture?
    --  How is confidentiality and publication managed?
    --  How are disputes to be resolved?
    --  Under what conditions can the deal be terminated?
    --  What happens when there is a change of ownership?
    --  What sublicensing and subcontracting provisions have been agreed?
    --  Which boilerplate clauses does the company insist upon?
    --  Which boilerplate clauses appear to differ from partner to partner or
        deal type to deal type?
    --  Which jurisdiction does the company insist upon for agreement law?

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Targeted Drug Delivery dealmaking

2.1. Introduction
2.2. Targeted Drug Delivery partnering over the years
2.3. Most active Targeted Drug Delivery dealmakers
2.4. Targeted Drug Delivery partnering by deal type
2.5. Targeted Drug Delivery partnering by therapy area
2.6. Deal terms for Targeted Drug Delivery partnering
2.6.1 Targeted Drug Delivery partnering headline values
2.6.2 Targeted Drug Delivery deal upfront payments7
2.6.3 Targeted Drug Delivery deal milestone payments
2.6.4 Targeted Drug Delivery royalty rates

Chapter 3 - Leading Targeted Drug Delivery deals

3.1. Introduction
3.2. Top Targeted Drug Delivery deals by value

Chapter 4 - Most active Targeted Drug Delivery dealmakers

4.1. Introduction
4.2. Most active Targeted Drug Delivery dealmakers
4.3. Most active Targeted Drug Delivery partnering company profiles

Chapter 5 - Targeted Drug Delivery contracts dealmaking directory

5.1. Introduction
5.2. Targeted Drug Delivery contracts dealmaking directory

Chapter 6 - Targeted Drug Delivery dealmaking by technology type

Chapter 7 - Partnering resource center

7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

Appendices

Appendix 1 - Targeted Drug Delivery deals by company A-Z

Appendix 2 - Targeted Drug Delivery deals by stage of development

Discovery
Preclinical
Phase I
Phase II
Phase III
Regulatory
Marketed
Formulation

Appendix 3 - Targeted Drug Delivery deals by deal type

Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Litigation
Manufacturing
Marketing
Material transfer
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Technology transfer
Termination
Warranty

Appendix 4 - Targeted Drug Delivery deals by therapy area

Appendix 5 - Deal type definitions

For more information about this report visit https://www.researchandmarkets.com/research/4dcmx6/global_targeted?w=5

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/global-targeted-drug-delivery-partnering-deals-and-agreements-2012-2018-300791868.html

SOURCE Research and Markets